Radiosynthesis and quality assurance of 5-[124I]Iodo-2'-deoxyuridine for functional PET imaging of cell proliferation.
5-[124I]Iodo-2'-deoxyuridine ([124I]IUdR) was routinely produced by direct electrophilic labelling of 2'-deoxyuridine with 124I of high specific activity (12 Ci/micromol) in an Iodogen-coated ReactiVial, followed by purification on a Sep-Pak C-18 cartridge. The radiochemical purity was determined by TLC on a Silicagel-60 plate and by reverse-phase HPLC on a RP-18 column. Based upon 45 syntheses, the yield ranged from 45% to 65%. The radiochemical impurity of [124I]IUdR was determined at 2.9% by TLC (mainly iodate) and 4.3% by HPLC. The chemical stability of the solvated formulation allowed a time window of 2 days following end of synthesis (EOS) for chemical application, based upon the required 95% radiochemical purity grade of [124I]IUdR. The labelled compound was routinely used for the clinical determination of cell proliferation in glioma patients by positron emission tomography.
Guenther
I
I
Pet Programme, Paul Scherrer Institute, Villigen-Psi, Switzerland.
Wyer
L
L
Knust
E J
EJ
Finn
R D
RD
Koziorowski
J
J
Weinreich
R
R
D002455:Cell Division / Q000528:radiation effects; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D005910:Glioma / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D007065:Idoxuridine / Q000138:chemical synthesis* / Q000737:chemistry; D007457:Iodine Radioisotopes; D011785:Quality Assurance, Health Care; D014055:Tomography, Emission-Computed
D007457:Iodine Radioisotopes; D007065:Idoxuridine